Literature DB >> 28849606

Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study.

Etienne Gayat1, Mattia Arrigo1,2, Simona Littnerova3, Naoki Sato4, Jiri Parenica5, Shiro Ishihara4, Jindrich Spinar5, Christian Müller6, Veli-Pekka Harjola7, Johan Lassus8, Òscar Miró9, Aldo P Maggioni10, Khalid F AlHabib11, Dong-Ju Choi12, Jin Joo Park12, Yuhui Zhang13, Jian Zhang13, James L Januzzi14, Katsuya Kajimoto15, Alain Cohen-Solal16, Alexandre Mebazaa1.   

Abstract

AIMS: Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin-angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient's condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival. METHODS AND
RESULTS: The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46-0.69; and HR 0.53, 95% CI 0.42-0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone.
CONCLUSIONS: Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.
© 2017 The Authors. European Journal of Heart Failure © 2017 European Society of Cardiology.

Entities:  

Keywords:  Acute heart failure; Oral therapy; Prognosis

Mesh:

Substances:

Year:  2017        PMID: 28849606     DOI: 10.1002/ejhf.932

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  19 in total

1.  Morphine in acute heart failure: good in relieving symptoms, bad in improving outcomes.

Authors:  Òscar Miró; Víctor Gil; W Frank Peacock
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 2.  Improving Postdischarge Outcomes in Acute Heart Failure.

Authors:  Ovidiu Chioncel; Sean P Collins; Andrew P Ambrosy; Peter S Pang; Elena-Laura Antohi; Vlad Anton Iliescu; Aldo P Maggioni; Javed Butler; Alexandre Mebazaa
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

3.  Our Experience With Sacubitril/Valsartan in Chronic Heart Failure Management - HFrEF in the Ambulatory Setting.

Authors:  Nabil Naser; Mehmed Kulić; Zaim Jatić
Journal:  Med Arch       Date:  2022-04

4.  Risk stratification scores for patients with acute heart failure in the Emergency Department: A systematic review.

Authors:  Òscar Miró; Xavier Rossello; Elke Platz; Josep Masip; Danielle M Gualandro; W Frank Peacock; Susanna Price; Louise Cullen; Salvatore DiSomma; Mucio Tavares de Oliveira; John Jv McMurray; Francisco J Martín-Sánchez; Alan S Maisel; Christiaan Vrints; Martin R Cowie; Héctor Bueno; Alexandre Mebazaa; Christian Mueller
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2020-08

Review 5.  Optimising Heart Failure Therapies in the Acute Setting.

Authors:  Mattia Arrigo; Petra Nijst; Alain Rudiger
Journal:  Card Fail Rev       Date:  2018-05

Review 6.  Assessment of acute heart failure prognosis: the promising role of prognostic models and biomarkers.

Authors:  Nikolaos P E Kadoglou; John Parissis; Apostolos Karavidas; Ioannis Kanonidis; Marialena Trivella
Journal:  Heart Fail Rev       Date:  2021-05-25       Impact factor: 4.214

7.  Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.

Authors:  Valentina Carubelli; Carlo Lombardi; Claudia Specchia; Giulia Peveri; Chiara Oriecuia; Daniela Tomasoni; Mattia Di Pasquale; Riccardo Inciardi; Emirena Garrafa; Marco Metra
Journal:  ESC Heart Fail       Date:  2021-03-04

8.  Usefulness of a personalized algorithm-based discharge checklist in patients hospitalized for acute heart failure.

Authors:  Florent Allain; Virginie Loizeau; Laure Chaufourier; Maya Hallouche; Laurence Herrou; Amir Hodzic; Katrien Blanchart; Annette Belin; Alain Manrique; Paul Milliez; Rémi Sabatier; Damien Legallois
Journal:  ESC Heart Fail       Date:  2020-04-22

Review 9.  Acute heart failure.

Authors:  Mattia Arrigo; Mariell Jessup; Wilfried Mullens; Nosheen Reza; Ajay M Shah; Karen Sliwa; Alexandre Mebazaa
Journal:  Nat Rev Dis Primers       Date:  2020-03-05       Impact factor: 52.329

10.  Reasons for Guideline Nonadherence at Heart Failure Discharge.

Authors:  Lauren G Gilstrap; Lynne W Stevenson; Roy Small; Ron Parambi; Rose Hamershock; Jeffrey Greenberg; Christina Carr; Roya Ghazinouri; Lisa Rathman; Elizabeth Han; Mandeep R Mehra; Akshay S Desai
Journal:  J Am Heart Assoc       Date:  2018-08-07       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.